- CO2 reactivity is the process by which PaCO2 affects CBF → cerebral vasculature.
- Within the normal range of PaCO2 between 20 and 60 mmHg, every 1 mmHg fluctuation results in 2% to 3% change in CBF.
- Hypercarbia (hypoventilation) → Vasodilation → increased CBF
- Hypocarbia (hyperventilation) → Vasorestriction → decrease CBF
- Mediated through changes in pH of the perivascular space via carbonic anhydrase,
- This forms the basis of the acetazolamide challenge
- Technique
- Acetazolamide 1 g IV
- Normal response:
- Acetazolamide → inhibits CA → reduce H+ and HCO3- production → dec. pH → Vasodilation and augmentation of CBF to 30 – 60% over 10– 15 minutes.
- Abnormal response
- A failure to vasodilate in response to acetazolamide implies maximal vasodilation, usually resulting from chronic ischaemia.
- Hyperaemia and metabolic acidosis in CSF
- Are associated with the acute phase of TBI
- Occur in the first 24 hours
- Patients with persistent loss of CO2 reactivity risk high mortality or severe neurological compromise.
- While CO2 reactivity causes changes in both CBF and AVDO2 (Arterio-jugular differences of oxygen)
- Autoregulation affects CBF with AVDO2 maintained relatively constant.
- Hyperventilation and control of PaCO2 are important therapeutic interventions in the management of raised ICP,
- However this requires cerebral oxygenation monitoring to ensure that excessive arterial vasoconstriction does not inflict ischaemia.